Literature DB >> 26940167

Bupropion Hydrochloride.

S R Khan1, R T Berendt1, C D Ellison1, A B Ciavarella1, E Asafu-Adjaye1, M A Khan2, P J Faustino1.   

Abstract

Bupropion hydrochloride is a norepinephrine-dopamine disinhibitor (NDDI) approved for the treatment of depression and smoking cessation. Bupropion is a trimethylated monocyclic phenylaminoketone second-generation antidepressant, which differs structurally from most antidepressants, and resides in a novel mechanistic class that has no direct action on the serotonin system. Comprehensive chemical, physical, and spectroscopic profiles are presented. This analytical profile provides an extensive spectroscopic investigation utilizing mass spectrometry, one- and two-dimensional NMR, solid-state NMR, IR, NIR, Raman, UV, and X-ray diffraction. The profile also includes significant wet chemistry studies for pH, solubility, solution, and plasma stability. Both HPLC and UPLC methodology are presented for bupropion and its related impurities or major metabolites. The profile concludes with an overview of biological properties that includes toxicity, drug metabolism, and pharmacokinetics.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aminoketone; Antidepressant; Bupropion hydrochloride; Norepinephrine-dopamine disinhibitor and stability

Mesh:

Substances:

Year:  2016        PMID: 26940167     DOI: 10.1016/bs.podrm.2015.12.001

Source DB:  PubMed          Journal:  Profiles Drug Subst Excip Relat Methodol        ISSN: 1871-5125


  6 in total

1.  A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms.

Authors:  Nan-Hung Hsieh; Frédéric Y Bois; Eleftheria Tsakalozou; Zhanglin Ni; Miyoung Yoon; Wanjie Sun; Martin Klein; Brad Reisfeld; Weihsueh A Chiu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-22       Impact factor: 2.410

2.  Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures.

Authors:  Angeliki Siamidi; Aikaterini Dedeloudi; Marilena Vlachou
Journal:  Polymers (Basel)       Date:  2021-04-30       Impact factor: 4.329

3.  Second-generation antidepressants for treatment of seasonal affective disorder.

Authors:  Barbara Nussbaumer-Streit; Kylie Thaler; Andrea Chapman; Thomas Probst; Dietmar Winkler; Andreas Sönnichsen; Bradley N Gaynes; Gerald Gartlehner
Journal:  Cochrane Database Syst Rev       Date:  2021-03-04

4.  Use of Bupropion in the Management of Negative Symptom Schizophrenia: A Case Series.

Authors:  Pradilka Perera; Ganeya Gajaram; Danish Qureshi; Manpreet Gill; Amod Thanju; Afrina Zaman; Patrice Fouron; Ayodeji Jolayemi
Journal:  Cureus       Date:  2022-03-26

5.  Naltrexone alters cardiovascular function following acute forced swimming in mice.

Authors:  Candace R Longoria; Quadratullah Qadiri; Evan L Matthews; Sara C Campbell; John J Guers
Journal:  Cardiovasc Endocrinol Metab       Date:  2022-04-13

Review 6.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.